Company / Depreciation & Amortization
CRISPR Therapeutics AG Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$19.5M
FY2025
5-year range
$18.0M / $24.2M
FY2021-FY2025
Trend
+1.1%
vs FY2024
Sector context
#44 of 162
Health Care
What the data says
At $19M, CRISPR Therapeutics AG's depreciation & amortization ranks #119 of 162 in the Health Care sector. Depreciation & Amortization returned to growth in FY2025 after 2 years of decline, reaching $19M.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of +16.2%.
Remained stable around $19M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- +16.2%
- 10-Year CAGR
- -
Sector benchmark
#119 of 162 in Health CareTop 73% of 162This company $19.5M Sector average $220.5M
▼
-91.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.2%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 1.1% year-over-year.
- Ranks #44 out of 162 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.5M | +1.1% |
| FY2024 | $19.3M | -2.9% |
| FY2023 | $19.8M | -17.9% |
| FY2022 | $24.2M | +34.6% |
| FY2021 | $18.0M | +95.5% |
| FY2020 | $9.2M | +94.4% |
| FY2019 | $4.7M | +34.3% |
| FY2018 | $3.5M | +16.4% |
| FY2017 | $3.0M | +226.9% |
| FY2016 | $925.0K | +628.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026